Juan G. Correa
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.
Journal: HemaSphere
Published: December 28, 2025
Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma and Tuberculosis: A Rare Association With Diagnostic and Therapeutic Challenges.
Journal: Journal of medical cases
Published: November 18, 2025
Combining CAR T-Cell Therapy and Nivolumab to Overcome Immune Resistance in THRLBCL: A Case Report.
Journal: International journal of molecular sciences
Published: July 31, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.
Journal: HemaSphere
Published: February 25, 2025
The genomic landscape of transformed splenic diffuse red pulp small B-cell lymphoma.
Journal: EJHaem
Published: June 11, 2024
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: British journal of haematology
Published: September 05, 2023
A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma.
Journal: Hematological oncology
Published: May 24, 2023
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals.
Journal: The Journal of antimicrobial chemotherapy
Published: October 26, 2022
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Journal: British journal of haematology
Published: July 08, 2022
Last Updated: 09/26/2026